Egawa Shunya, Shimane Toshikazu, Akiyama Rio, Ikenoya Yoichi, Uzuki Aya, Sugimoto Akane, Hayashi Takeshi, Ikeda Kenichirou, Sanbe Takeyuki
Dept. of Otorhinolaryngology, Showa University Fujigaoka Hospital.
Gan To Kagaku Ryoho. 2011 Aug;38(8):1301-5.
Laryngeal cancer is one of the most common types of head and neck cancer. Numerous studies have reported treatment outcomes, and therapeutic approaches and results are generally well established. However, the widespread use of concurrent chemoradiation therapy(CCRT)has led to differences among hospitals in laryngeal preservation rates in patients with T2 and T3 tumors. CCRT is the mainstay of treatment for laryngeal cancer in our department, given our goals of achieving organ and functional preservation, as well as radical cure. Our regimen for CCRT is comprised of chemotherapy with S-1 plus nedaplatin, concurrently with radiation therapy(SN therapy). We report outcomes obtained from 60 patients with laryngeal cancer who received first-line treatment in our department from April 2005 through March 2010. Cumulative survival rates according to disease stage were as follows: Stage I, 100%; Stage II, 96. 2%; Stage III, 83. 3%; and Stage IV, 48. 8%. The complete response rate after SN therapy was 84. 3%. After excluding patients with T4 tumors, the laryngeal preservation rate was 85. 7%.
喉癌是头颈癌最常见的类型之一。众多研究报告了治疗结果，治疗方法和结果总体上已得到充分确立。然而，同步放化疗（CCRT）的广泛应用导致不同医院在T2和T3肿瘤患者的喉保留率上存在差异。鉴于我们实现器官和功能保留以及根治的目标，CCRT是我们科室喉癌治疗的主要方法。我们的CCRT方案包括S-1加奈达铂化疗，同时进行放射治疗（SN疗法）。我们报告了2005年4月至2010年3月期间在我们科室接受一线治疗的60例喉癌患者的治疗结果。根据疾病分期的累积生存率如下：I期，100%；II期，96.2%；III期，83.3%；IV期，48.8%。SN治疗后的完全缓解率为84.3%。排除T4肿瘤患者后，喉保留率为85.7%。
